Barclays PLC lessened its holdings in Cerus Co. (NASDAQ:CERS) by 19.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,418 shares of the biotechnology company’s stock after selling 18,936 shares during the period. Barclays PLC owned about 0.06% of Cerus worth $409,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Aperio Group LLC acquired a new stake in shares of Cerus in the 2nd quarter worth about $27,000. Meristem Family Wealth LLC bought a new stake in Cerus in the 2nd quarter worth about $56,000. Jefferies Group LLC bought a new stake in Cerus in the 2nd quarter worth about $75,000. Jane Street Group LLC bought a new stake in Cerus in the 2nd quarter worth about $93,000. Finally, Cubist Systematic Strategies LLC grew its position in Cerus by 1,108.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 20,551 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 18,851 shares in the last quarter. Institutional investors own 75.02% of the company’s stock.

In other news, SVP Carol Moore sold 30,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $5.33, for a total transaction of $159,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gail Schulze sold 15,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $4.19, for a total transaction of $62,850.00. Following the transaction, the director now directly owns 40,986 shares of the company’s stock, valued at $171,731.34. The disclosure for this sale can be found here. 7.26% of the stock is owned by corporate insiders.

A number of brokerages have issued reports on CERS. BTIG Research raised shares of Cerus from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Wednesday, November 13th. Stifel Nicolaus began coverage on shares of Cerus in a research report on Tuesday, August 27th. They issued a “buy” rating and a $7.00 price objective for the company. Stephens began coverage on shares of Cerus in a research report on Thursday, August 22nd. They issued an “overweight” rating and a $8.00 price objective for the company. Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a research report on Monday, October 7th. Finally, BidaskClub downgraded shares of Cerus from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Shares of CERS stock opened at $3.99 on Friday. Cerus Co. has a 52-week low of $3.70 and a 52-week high of $6.88. The company has a debt-to-equity ratio of 0.95, a quick ratio of 2.31 and a current ratio of 2.77. The company has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $4.90. The company has a market capitalization of $569.00 million, a price-to-earnings ratio of -9.07 and a beta of 1.57.

Cerus (NASDAQ:CERS) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). Cerus had a negative net margin of 100.38% and a negative return on equity of 100.59%. The company had revenue of $18.00 million for the quarter, compared to the consensus estimate of $17.69 million. During the same period in the prior year, the company earned ($0.11) earnings per share. The firm’s revenue was up 16.9% on a year-over-year basis. On average, sell-side analysts forecast that Cerus Co. will post -0.5 EPS for the current fiscal year.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Story: Rule of 72

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.